Chandra Mohan, Hugh Roy and Lillie Cranz Cullen Endowed Professor of biomedical engineering, is reporting the first use of the powerful imaging mass cytometry (IMC) to examine the kidneys of patients with lupus (systemic lupus erythematosus), an autoimmune disease that can affect multiple organs and become fatal, and to diagnose lupus nephritis (LN) in those… Continue reading Powerful imaging mass cytometry could revolutionize the diagnosis of lupus nephritis
Tag: Autoimmunity and Autoimmune Diseases
Therapeutic Modalities and Clinical Outcomes in a Large Cohort with LRBA Deficiency and CTLA4 Insufficiency
T-cell tolerant fraction as a predictor of immune-related adverse events
Background Immune checkpoint inhibitor (ICI) therapies may cause unpredictable and potentially severe autoimmune toxicities termed immune-related adverse events (irAEs). Because T cells mediate ICI effects, T cell profiling may provide insight into the risk of irAEs. Here we evaluate a novel metric—the T-cell tolerant fraction—as a predictor of future irAEs. Methods We examined T-cell receptor… Continue reading T-cell tolerant fraction as a predictor of immune-related adverse events
C-Path and Sanofi collaborate to advance Type 1 Diabetes research
Critical Path Institute (C-Path) announced today that Sanofi, a global leader in immunology and diabetes care, has joined its Type 1 Diabetes Consortium (T1DC) The consortium achieves this by fostering collaborative relationships within the broader T1D community and sharing data, knowledge and resources to promote the development and regulatory endorsement of novel drug development tools… Continue reading C-Path and Sanofi collaborate to advance Type 1 Diabetes research
A new ally in fighting brain diseases: Our very own skull
Alzheimer’s, stroke, multiple sclerosis and other neurological diseases cause severe damage due to neuroinflammation mediated by immune cells. Managing this inflammation poses a significant medical challenge because the brain is protected by the skull and additional surrounding membranes that make the brain less accessible for treatment approaches. Scientists had previously discovered pathways going from the… Continue reading A new ally in fighting brain diseases: Our very own skull
Engineered probiotic developed to treat multiple sclerosis
Researchers have designed a probiotic to suppress autoimmunity in the brain, which occurs when the immune system attacks the cells of the central nervous system.
Lymph node sharing between pancreas, gut, and liver leads to immune crosstalk and regulation of pancreatic autoimmunity
Lymph nodes (LNs) are critical for surveilling the tissue they drain. How LNs integrate and respond to complex cues in the situation of LN sharing between organs is unknown. Brown and Komnick et al. discover that LN co-drainage between the pancreas, gut, and liver leads to immune crosstalk, impacting pancreatic autoimmunity.
New Approaches to Challenge Old Assumptions—B-Cell Depletion in Multiple Sclerosis
B-cell–depleting monoclonal antibodies (mAbs) have emerged as an arguably mechanistically dominant drug class in the multiple sclerosis (MS) disease-modifying therapy (DMT) armamentarium in recent years. As a group, they represent a high-efficacy treatment option for relapsing MS and offer some degree of efficacy in progressive forms of MS. Ocrelizumab remains the only DMT approved for… Continue reading New Approaches to Challenge Old Assumptions—B-Cell Depletion in Multiple Sclerosis
Initiation Patterns of Disease-Modifying Therapies for Multiple Sclerosis Among US Adults and Children, 2001-2020
This study evaluates patterns in disease-modifying therapy initiations between 2001 and 2020 among commercially insured US adults and children with multiple sclerosis.
Rituximab vs Ocrelizumab in Relapsing-Remitting Multiple Sclerosis
AI SummaryThis cohort study compares the effectiveness of rituximab and ocrelizumab in preventing relapses and disability in patients with relapsing-remitting multiple sclerosis.This cohort study investigates if rituximab is noninferior to ocrelizumab in the prevention of relapses and disability in patients with relapsing-remitting multiple sclerosis.